Literature DB >> 9307199

Mode of chemotherapy does not affect complications with an implantable venous access device.

D F Brown1, M J Muirhead, P M Travis, S R Vire, J Weller, M Hauer-Jensen.   

Abstract

BACKGROUND: Few reports have been made regarding the long term safety of implantable venous access devices used for the delivery of chemotherapeutic agents. The authors' goals were to determine the frequency of complications in patients receiving chemotherapy with these devices; to determine whether complications were associated with the mode of chemotherapy delivery (push/bolus or infusional regimens); and to evaluate the influence of other risk factors, including home-based versus hospital-based administration.
METHODS: A total of 152 oncology patients at the John L. McClellan Memorial Veterans Administration Medical Center in Little Rock, Arkansas (ages 26-81 years; mean age, 62 years), who underwent surgical placement of an Infus-a-Port (Strato, Inc., Beverly, MA) between May 1, 1992 and May 31, 1994, were evaluated retrospectively for postplacement device complications, such as infection, thrombosis, and mechanical failure.
RESULTS: Twenty-seven patients experienced 1 complication each: 17 episodes of device-related sepsis, cellulitis, or fever of unknown origin; 8 episodes of thrombosis or catheter occlusion; 1 episode of drug extravasation; and 1 mechanical failure. Patient age, frequency of port accession, mode of chemotherapy delivery, tumor type, and neutropenia were evaluated as risk factors, but none was statistically significant. Complications were more frequent during the first 90 days after implantation, but they continued to occur throughout the observation period.
CONCLUSIONS: Complications attributable to an implantable venous access device were infrequent in this patient population. No differences in complications for patients receiving home-based versus hospital-based chemotherapy administration were noted, opening the possibility of significant time and cost savings with home treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9307199     DOI: 10.1002/(sici)1097-0142(19970901)80:5<966::aid-cncr20>3.0.co;2-t

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  8 in total

Review 1.  Systematic review: malfunction of totally implantable venous access devices in cancer patients.

Authors:  Godelieve Alice Goossens; Marguerite Stas; Martine Jérôme; Philip Moons
Journal:  Support Care Cancer       Date:  2011-05-10       Impact factor: 3.603

2.  It appears to be safe to start chemotherapy on the day of implantation through subcutaneous venous port catheters in inpatient setting.

Authors:  Nuriye Yildirim Ozdemir; Hüseyin Abali; Berna Oksüzoğlu; Burçin Budakoğlu; Ilkay Akmangit; Nurullah Zengin
Journal:  Support Care Cancer       Date:  2008-09-02       Impact factor: 3.603

3.  Cutaneous bacterial colonization, modalities of chemotherapeutic infusion, and catheter-related bloodstream infection in totally implanted venous access devices.

Authors:  L Laurenzi; S Natoli; C Benedetti; M E Marcelli; W Tirelli; L DiEmidio; E Arcuri
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

4.  Incidents and complications of permanent venous central access systems: a series of 1,460 cases.

Authors:  Massine El Hammoumi; Mohammed El Ouazni; Adil Arsalane; Fayçal El Oueriachi; Hamid Mansouri; El Hassane Kabiri
Journal:  Korean J Thorac Cardiovasc Surg       Date:  2014-04-10

5.  Totally Implantable Venous Access Device (Chemoport) in Oncology: Study of 168 Polyurethane Chemoport Catheter System.

Authors:  Gyanendra Swaroop Mittal; Deepak Sundriyal; Niranjan B Naik; Amit Sehrawat
Journal:  South Asian J Cancer       Date:  2021-12-31

6.  Extravasation injuries in adults.

Authors:  S Al-Benna; C O'Boyle; J Holley
Journal:  ISRN Dermatol       Date:  2013-05-08

7.  Home administration of maintenance pemetrexed for patients with advanced non-squamous non-small cell lung cancer: rationale, practicalities and phase II feasibility study design.

Authors:  Rohit Lal; Nawel Bourayou; Gunnar Hillerdal; Marianne Nicolson; Anders Vikstrom; Maria Lorenzo; Yulia D'yachkova; Susana Barriga; Carla Visseren-Grul
Journal:  Health Qual Life Outcomes       Date:  2013-10-03       Impact factor: 3.186

8.  Incidence and risk factors of infectious complications related to implantable venous-access ports.

Authors:  Jisue Shim; Tae-Seok Seo; Myung Gyu Song; In-Ho Cha; Jun Suk Kim; Chul Won Choi; Jae Hong Seo; Sang Cheul Oh
Journal:  Korean J Radiol       Date:  2014-07-09       Impact factor: 3.500

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.